Trial Profile
Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral Medication: The TAF-IR Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/rilpivirine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms The TAF-IR Study
- 27 Aug 2018 Primary endpoint (Changes in insulin sensitivity) has not been met, according to results presented at the 22nd International AIDS Conference.
- 27 Jul 2018 Results presented at the 22nd International AIDS Conference.
- 16 Aug 2017 Status changed from recruiting to completed.